Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBK9PS)

Drug Name

AM-404 Drug Info

Synonyms

AM 404; AM-404; 183718-77-6; am404; UNII-XVJ94H0U21; 198022-70-7; CHEMBL39878; XVJ94H0U21; CPD000449274; (5Z,8Z,11Z,14Z)-N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide; N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide; SMR000449274; SR-01000597390; N-(4-Hydroxyphenyl)-arachidonylamide; N-(4-Hydroxyphenyl)arachidonylamide; N-(4-Hydroxyphenyl)arachidonoyl amide; NCGC00025010-01; Tocris-1116; AC1O7GXA; 5,8,11,14-Eicosatetraenamide, N-(4-hydroxyphenyl)-, (all-Z)-; N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 6604822
CAS Number: CAS 183718-77-6
TTD Drug ID: DMBK9PS

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Fatty acid amide hydrolase (FAAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[5]
Thiopental	DMGP8AX	Anaesthesia	9A78.6	Approved	[6]
JNJ-42165279	DM72GZO	Anxiety disorder	6B00-6B0Z	Phase 2	[7]
SSR411298	DMGTB2Q	Major depressive disorder	6A70.3	Phase 2	[8]
IW-6118	DMP42W1	Inflammation	1A00-CA43.1	Phase 2	[9]
PF-04457845	DMPRYU1	Liver disease	DB90-BD99	Phase 2	[10]
IPI-940	DMEIM5G	Pain	MG30-MG3Z	Phase 1	[11]
PMID29053063-Compound-11d	DMDRK68	N. A.	N. A.	Patented	[12]
Piperazine carbamic compound 1	DMZSYU4	N. A.	N. A.	Patented	[12]
Piperazine carbamic compound 2	DMMQ0ZO	N. A.	N. A.	Patented	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cannabinoid receptor 2 (CB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[13]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[14]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[15]
KHK-6188	DMF6CTI	Neuropathic pain	8E43.0	Phase 2	[16]
LY-2828360	DMO8IEZ	Pain	MG30-MG3Z	Phase 2	[16]
APD371	DM3XT5V	Crohn disease	DD70	Phase 2	[17]
S-777469	DMZGNOJ	Atopic dermatitis	EA80	Phase 2	[18]
842166X	DMOV0AP	Pain	MG30-MG3Z	Phase 2	[19]
Beta-caryophyllene	DM7583A	Pain	MG30-MG3Z	Phase 2	[20]
Vicasinabin	DMF16CU	Diabetic retinopathy	9B71.0	Phase 2	[21]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[22]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[14]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[23]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[24]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[25]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[26]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[15]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[27]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[28]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[29]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[30]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[31]
Fructose	DM43AN2	Vomiting	MD90	Approved	[32]
Ketoprofen	DMRKXPT	Bursitis		Approved	[32]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[33]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[34]
Baclofen	DM0QV1J	Multiple sclerosis	8A40	Approved	[35]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[36]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[37]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[40]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[41]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[44]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[45]
Hydroxychloroquine	DMSIVND	Chronic renal failure	GB61.Z	Approved	[46]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[47]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[48]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Transient receptor potential cation channel subfamily V member 1 (TRPV1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[49]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[50]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[51]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[52]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[53]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[55]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[56]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[57]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[58]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Inhibitor	[1]
Cannabinoid receptor 2 (CB2)	TTMSFAW	CNR2_HUMAN	Inhibitor	[2]
Fatty acid amide hydrolase (FAAH)	TTDP1UC	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2)	OTK5T6HZ	NFAC2_HUMAN	Gene/Protein Processing	[3]
Transient receptor potential cation channel subfamily V member 1 (TRPV1)	OTHHDR03	TRPV1_HUMAN	Gene/Protein Processing	[4]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Gene/Protein Processing	[3]

------------------------------------------------------------------------------------

References

1	Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem. 1996 Oct 25;39(22):4515-9.
2	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
3	The acetaminophen-derived bioactive N-acylphenolamine AM404 inhibits NFAT by targeting nuclear regulatory events. Biochem Pharmacol. 2007 Apr 1;73(7):1013-23. doi: 10.1016/j.bcp.2006.12.001. Epub 2006 Dec 15.
4	"TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure". Channels (Austin). 2019 Dec;13(1):1-16. doi: 10.1080/19336950.2018.1547611.
5	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
6	The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
9	The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
10	Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
12	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
13	Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
14	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
15	Company report (Gwpharm)
16	Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
17	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18	Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
19	The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
20	The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
21	Clinical pipeline report, company report or official report of Roche
22	Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
23	Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
24	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
25	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
26	Clinical pipeline report, company report or official report of AstraZeneca (2009).
27	Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
28	Clinical pipeline report, company report or official report of Bird Rock Bio.
29	Clinical pipeline report, company report or official report of Affimed Therapeutics.
30	Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
31	A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. Toxicol Appl Pharmacol. 2017 Nov 1;334:18-23. doi: 10.1016/j.taap.2017.08.017. Epub 2017 Sep 1.
32	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
33	CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
34	Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
35	Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
36	Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
37	Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
38	Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
39	Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
40	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
41	Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
42	Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
43	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
44	Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
45	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
46	Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res Ther. 2017 Aug 9;19(1):183. doi: 10.1186/s13075-017-1393-y.
47	Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
48	Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014 Apr 23;14:283.
49	Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001 Oct;134(4):845-52. doi: 10.1038/sj.bjp.0704327.
50	Comparison of protective effect of ascorbic acid on redox and endocannabinoid systems interactions in in vitro cultured human skin fibroblasts exposed to UV radiation and hydrogen peroxide. Arch Dermatol Res. 2017 May;309(4):285-303. doi: 10.1007/s00403-017-1729-0. Epub 2017 Mar 11.
51	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
52	Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
53	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
54	Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
55	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
56	The anthelminthic drug praziquantel is a selective agonist of the sensory transient receptor potential melastatin type 8 channel. Toxicol Appl Pharmacol. 2017 Dec 1;336:55-65. doi: 10.1016/j.taap.2017.10.012. Epub 2017 Oct 18.
57	Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004 Mar;13(3):129-39. doi: 10.1111/j.0906-6705.2004.0178.x.
58	The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons. J Clin Invest. 2008 Feb;118(2):763-76. doi: 10.1172/JCI32751.